This article was originally published in Start Up
It's truism in spine that 4% of patients rack up 75% in costs, and expensive BMP products, which are highly successful at enhancing fusion rates, are the "high octane" products for more difficult cases-high-risk patients or the obese, for example. The market needs a product for the majority of cases, believes the founder of CeraPedics LLC, and he believes his company has it in its P-15, a growth factor that's a small peptide.
You may also be interested in...
Bone Biologics' protein for stimulating bone growth was originally isolated from areas of active bone growth in humans. Based on animal studies to date, the company's founders claim that its UCB-1, performs as well if not better than marketed BMPs because of its molecular specificity. The company plans to combine UCB-1 with a proprietary scaffold to create biological solutions to a number of bone disorders.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.